CHARLOTTE, N.C.--(BUSINESS WIRE)--PeraHealth, an innovative provider of predictive, real-time clinical surveillance solutions, celebrates 10 years of lifesaving intelligence by introducing the Rothman Society for Innovation and Research, a dedicated organization created to house all research associated with the Rothman Index (RI) and its application. This effort continues the work begun by brothers Michael and Steven Rothman, who turned the loss of their mother, Florence Rothman, into a passion for saving lives by developing the RI a decade ago, and now expands to include other healthcare industry thought leaders.
The Society’s inaugural research is focused on two major healthcare issues: sepsis and readmissions. The Society will expand its sepsis work with a prospective study in hospital environments for a RI sepsis- specific model, expanding on earlier sepsis research that was published in the Journal of Critical Care. The research team is also in the midst of a study to expand how the RI can best be used to help predict readmission risk and enable reduced readmission rates over time. PeraHealth currently has case studies supporting readmissions work in conjunction with skilled nursing facilities.
The Rothman Society for Innovation and Research builds on the breakthrough work foundational to proven PeraHealth results, which already includes nearly 100 peer-reviewed articles, oral presentations and posters. It houses all research, testing and development for expanding RI application to improve quality, safety and outcomes.
“In understanding physiological deterioration, we have this window that no one has ever looked through—and it gives us a tremendous insight into the patient condition based on physiological measures. The creation of the Rothman Index was the commencement of our work and we’ve only just scratched the surface,” says Michael Rothman, PeraHealth’s co-founder and Chief Science Officer, in an exclusive video message. “The Society will leverage other like-minded industry luminaries to advance our original purpose: to transform healthcare through the intelligent use of data.”
Society membership is open to anyone wishing to engage in rigorous scientific discussion around refining and applying the RI. Current PeraHealth customers are automatically enrolled as lifetime members. Other welcome participants include academic centers, payers, pharmaceutical and medical device manufacturers, and independent researchers. Members share the benefits of research support, research participation and expert scientific guidance.
Register for the first Rothman Society webinar on June 7, 2018, from 1-2 p.m. ET, for an update on in-progress research and the Society’s next steps.
For more information on partnering with the Society, visit www.rothmansociety.com.
About the Rothman Index
The RI has emerged as the clinical gold standard for visualizing and trending patient condition. All PeraHealth solutions are powered by the RI model, leveraging data in a hospital’s existing electronic health record (EHR) to quantify and visualize patient deterioration, risk and improvement in real time. While other solutions depend on vital signs alone, the peer-reviewed RI model uses a range of physiological measures – including labs, vital signs and nursing assessments – to produce a continuous measure of patient condition across diseases, conditions, and levels of care, trended over time. PeraTrend™ is now the first solution of its kind to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA).
PeraHealth is transforming healthcare through the intelligent use of data. PeraHealth solutions, powered by the Rothman Index, provide a visual representation of the patient’s condition and progress in real time. Leading hospitals and health systems use PeraHealth predictive analytics to improve quality reduce cost, and to help them achieve their goals of reducing all-cause mortality, length of stay, and readmissions. For more information, visit PeraHealth.com and @PeraHealth.